コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 were 125 mg (100 mg of levodopa and 25 mg of carbidopa).
2 ted when treated with higher doses of L-DOPA/Carbidopa.
3 mented visual improvement with levodopa plus carbidopa.
4 mask adrenal pheochromocytoma, is blocked by carbidopa.
5 PET with oral preadministration of 200 mg of carbidopa.
6 r tracer uptake by the tumors is enhanced by carbidopa.
7 ated empirically with levodopa combined with carbidopa.
8 PA in the presence of the co-drug compound L-carbidopa.
9 n humans after oral pretreatment with 100 mg carbidopa.
10 s altered significantly by pretreatment with carbidopa.
11 degeneration, and responsiveness to levodopa-carbidopa.
12 aneous ND0612 and 131 (51%) to oral levodopa-carbidopa.
14 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks (earl
15 4'-monophosphate, 3) and foscarbidopa (FCD, carbidopa 4'-monophosphate, 4) were identified as water-
16 h/day subcutaneous ND0612 infusion (levodopa-carbidopa 60.0/7.5 mg/mL), with supplemental oral levodo
17 udy whether human equivalent doses of L-DOPA/Carbidopa administered during the crucial postnatal peri
20 me involved in NE cell GABA metabolism, (ii) carbidopa, an inhibitor of dopa decarboxylase which func
22 ust be present at the aromatic ring of the l-carbidopa analogues and show that the presence of fluori
23 hed for both oral immediate-release levodopa-carbidopa and for 24 h/day subcutaneous ND0612 infusion
25 re 62.5 mg (50 mg of levodopa and 12.5 mg of carbidopa) and the remaining doses were 125 mg (100 mg o
27 sonism responsive to treatment with levodopa-carbidopa, and nine with central neurodegeneration unres
28 All patients who underwent (68)Ga-DOTATOC or carbidopa-assisted (18)F-DOPA PET/CT for suspicion of in
29 as to assess the value of (68)Ga-DOTATOC and carbidopa-assisted (18)F-fluorodihydroxyphenylalanine ((
30 treated with a 28-day course of oral L-DOPA/Carbidopa at 3 different doses from 15 to 43 days postna
31 ted twice daily with levodopa (15 mg/kg with carbidopa by oral gavage) for two weeks developed choreo
33 apy with the oral administration of levodopa/carbidopa can improve the vision of amblyopic children,
35 ter-soluble prodrugs of levodopa (LD, 1) and carbidopa (CD, 2), respectively, which are useful for th
36 esome dyskinesia compared with oral levodopa-carbidopa (change from baseline of -0.48 h [-0.94 to -0.
38 ults, pretreatment with the AADC inhibitor S-carbidopa did not affect the (18)F-l-FEHTP PET results.
39 tment of MPTP-treated marmosets with L-DOPA/ carbidopa did not alter the levels of specific [3H]7-OH-
42 allocated to immediate-release oral levodopa-carbidopa (difference -1.91 h [95% CI -3.05 to -0.76]; p
43 dyskinesia with long-term therapy, levodopa/carbidopa does not appear to be a viable option for ambl
48 rain stimulation and treatment with levodopa-carbidopa enteral suspension can help individuals with m
49 ced treatments such as therapy with levodopa-carbidopa enteral suspension or deep brain stimulation.
51 ompared with oral immediate-release levodopa-carbidopa for the treatment of motor fluctuations in peo
52 her low- or high-dose Sinemet (levodopa plus carbidopa) for 2 weeks and compared their ERG findings w
54 cated to the immediate-release oral levodopa-carbidopa group (seven [21%] serious), mainly associated
55 D0612 group vs 56 [43%] in the oral levodopa-carbidopa group during the double-blind phase), most of
57 group versus 42 (63%) of 67 in the levodopa-carbidopa group, and incidences of serious adverse event
60 dard and megadose corticosteroids, levodopa, carbidopa, hyperbaric oxygen, and neuroprotective agents
63 y included oral levodopa plus benserazide or carbidopa in a regimen that had been stable for 4 weeks
65 ination with oral immediate-release levodopa-carbidopa increased on time without troublesome dyskines
67 ed to assess efficacy and safety of levodopa-carbidopa intestinal gel delivered continuously through
68 PEG tube for continuous infusion of Levodopa/carbidopa intestinal gel for advanced Parkinson's diseas
69 5) for 35 patients allocated to the levodopa-carbidopa intestinal gel group compared with a decrease
70 5%) of 37 patients allocated to the levodopa-carbidopa intestinal gel group had adverse events (five
74 e show that over 1200 mg/day of 4:1 levodopa-carbidopa (LD-CD) can be non-invasively and continuously
75 dulation by systemic injection of L-DOPA and Carbidopa (LDC) or by local application of DA in V1 and
77 ime for IPX203 compared to immediate-release carbidopa-levodopa (least squares mean, 0.53 hours; 95%
78 s treated double-blind with extended-release carbidopa-levodopa (mean 3.6 doses per day [SD 0.7]) had
80 opa and 29.79% (15.81) for immediate-release carbidopa-levodopa (mean difference -5.97, 95% CI -9.05
82 were 23.82% (SD 14.91) for extended-release carbidopa-levodopa and 29.79% (15.81) for immediate-rele
83 re excluded (those taking controlled-release carbidopa-levodopa apart from a single daily bedtime dos
84 inson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 7
85 is an oral, extended-release formulation of carbidopa-levodopa developed to address these limitation
87 went 3 weeks of open-label immediate-release carbidopa-levodopa dose adjustment followed by 6 weeks o
89 release formulation versus immediate-release carbidopa-levodopa in patients with Parkinson's disease
94 ] of 201 patients allocated extended-release carbidopa-levodopa vs two [1%] of 192 patients allocated
95 ble-blind phase (IPX203 vs immediate-release carbidopa-levodopa) were nausea (4.3% vs 0.8%) and anxie
96 of 192 patients allocated immediate-release carbidopa-levodopa), nausea (six [3%] vs three [2%]), an
97 During dose conversion with extended-release carbidopa-levodopa, 23 (5%) of 450 patients withdrew bec
98 od response to dopaminergic medications (eg, carbidopa-levodopa, dopamine agonists), and slower disea
99 good on-time per day than immediate-release carbidopa-levodopa, even as IPX203 was dosed less freque
103 luding a new extended release formulation of carbidopa/levodopa (IPX066), safinamide which inhibits M
105 s per day with levodopa placebo (n = 42), or carbidopa/levodopa, 25/100 mg 3 times per day with prami
106 hanged little in the past decade and include carbidopa/levodopa, dopamine agonists, and monoamine oxi
109 and 66.7% (regions) for (18)F-DOPA PET plus carbidopa (neither is statistically significant vs. base
110 patients benefit dramatically from levodopa/carbidopa, often with further improvement with the addit
111 equently, we aimed to evaluate the effect of carbidopa on (18)F-FDOPA uptake in insulinoma beta-cells
112 Rytary (Amneal Pharmaceuticals), additional carbidopa or benserazide, or catechol O-methyl transfera
114 disease severity were administered 50 mg of carbidopa orally followed in 1 hour by an intravenous bo
115 2 vs. CT/MRI), and 57 by (18)F-DOPA PET plus carbidopa (P = 0.0075 vs. CT/MRI, not statistically sign
117 lacebo or to oral immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of place
118 oral encapsulated immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of place
119 eatment with immediate-release oral levodopa-carbidopa plus placebo intestinal gel infusion or levodo
123 opa is a soluble formulation of levodopa and carbidopa prodrugs that is delivered as a 24-h/day conti
126 subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) compared with oral immediate-release
127 Our results demonstrate that oral L-DOPA/Carbidopa supplementation at human equivalent doses duri
130 ; Study 2, n = 18) L-DOPA (administered with carbidopa) versus placebo would increase right amygdala-
131 ely diminished circling response when l-DOPA-carbidopa was repeatedly administered at 120 min interva
132 ne-proton exchangers VMAT1 and VMAT2, and by carbidopa, which inhibits aromatic L-amino acid decarbox
134 are precursors of fluorinated analogues of l-carbidopa, which is known to inhibit DOPA decarboxylase
135 pia therapy using up to 16 weeks of levodopa/carbidopa will result in meaningful improvement in visua
137 either subcutaneous ND0612 or oral levodopa-carbidopa, with matching oral or subcutaneous placebo gi